Resverlogix (FRA:RFS) Stock Based Compensation: €0.44 Mil (TTM As of Mar. 2026)


FRA:RFS Resverlogix Corp FRA:RFS
39 GF Score
Price €0.05
! 4 Warning Signs
View Full Analysis

What is Resverlogix Stock Based Compensation?

Resverlogix FRA:RFS +1.02% 39 Stock Based Compensation is €0.44 Mil as of Mar. 2026. GuruFocus rates FRA:RFS with a GF Score™ of 39/100. The stock has 4 warning signs investors should review.

Resverlogix's Stock Based Compensation for the three months ended in Mar. 2026 was €0.10 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Mar. 2026 was €0.44 Mil.

Resverlogix Stock Based Compensation Related Terms

Resverlogix Stock Based Compensation Historical Data

* Premium members only.

The historical data trend for Resverlogix's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Resverlogix Stock Based Compensation Chart

Resverlogix Annual Data
Trend Apr16 Apr17 Apr18 Apr19 Apr20 Dec21 Dec22 Dec23 Dec24 Dec25
Stock Based Compensation
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.32 2.26 1.15 0.29 0.40

Resverlogix Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Stock Based Compensation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.07 0.14 0.08 0.12 0.10
FRA:RFS
39GF Score
Resverlogix Corp FRA:RFS
Stock Based Compensation is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Resverlogix Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.44 Mil.

What does a Stock Based Compensation of €0.44 Mil mean?
Resverlogix (FRA:RFS) has a Stock Based Compensation of €0.44 Mil as of Mar. 2026. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Resverlogix and its competitors.
Is Resverlogix's Stock Based Compensation too high?
Resverlogix's current Stock Based Compensation is €0.44 Mil. Overall, Resverlogix has a GF Score™ of 39/100, reflecting its overall financial health beyond just this single metric.
How does Resverlogix's Stock Based Compensation compare to VRTX and REGN?
Resverlogix's Stock Based Compensation of €0.44 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Stock Based Compensation for a Biotechnology company?
A good Stock Based Compensation depends on the Biotechnology industry context. However, Stock Based Compensation should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Stock Based Compensation mean?
A high Stock Based Compensation can signal that a stock is expensive relative to its fundamentals. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Resverlogix and its competitors. Resverlogix's current Stock Based Compensation is €0.44 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Resverlogix stock overvalued right now?
Resverlogix (FRA:RFS) has a current Stock Based Compensation of €0.44 Mil. The current Stock Based Compensation is €0.44 Mil. Resverlogix's overall GF Score™ is 39/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Stock Based Compensation calculated?
Stock Based Compensation is calculated from a company's financial statements. For Resverlogix (FRA:RFS), the current Stock Based Compensation is €0.44 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Resverlogix Business Description

Other Exchanges RVXCF:USARVX:Canada
Address 4820 Richard Road SW, Suite 300, Calgary, AB, CAN, T3E 6L1
Resverlogix Corp clinical-stage biotechnology company. The company is developing apabetalone (RVX-208), a first-in-class, small molecule that is a selective BET (bromodomain and extra-terminal) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. Apabetalone is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. This selective inhibition of apabetalone on BD2 produces a specific set of biological effects with potentially important benefits for patients with chronic disease, including cardiovascular disease (CVD) and associated comorbidities, and COVID-19.
39GF Score

Get the complete analysis for FRA:RFS

Stock Based Compensation is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.05
Price